Holen Sie sich die Stockscreener-App
2.85
5.63%
-0.17
Handel nachbörslich:
2.94
0.09
+3.16%
Schlusskurs vom Vortag:
$3.02
Offen:
$3.06
24-Stunden-Volumen:
474.60K
Relative Volume:
1.11
Marktkapitalisierung:
$2.14M
Einnahmen:
$129.20K
Nettoeinkommen (Verlust:
$-14.46M
KGV:
-0.0441
EPS:
-64.68
Netto-Cashflow:
$-18.52M
1W Leistung:
-13.64%
1M Leistung:
-51.78%
6M Leistung:
-80.64%
1J Leistung:
-75.26%
1-Tages-Spanne:
$2.50
$3.50
1-Wochen-Bereich:
$2.50
$3.50
52-Wochen-Spanne:
$2.50
$18.72
Sonnet Biotherapeutics Holdings Inc Stock (SONN) Company Profile
Firmenname
Sonnet Biotherapeutics Holdings Inc
Sektor
Branche
Telefon
609-375-2227
Adresse
100 OVERLOOK CENTER, PRINCETON, NJ
Vergleichen Sie SONN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| SONN | 2.85 | 2.14M | 129.20K | -14.46M | -18.52M | -64.68 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Sonnet Biotherapeutics Holdings Inc Aktie (SONN) Neueste Nachrichten
Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment - GlobeNewswire
Sonnet BioTherapeutics Secures Crucial Patent for Novel Cancer Immunotherapy Pipeline | SONN Stock News - StockTitan
Sonnet BioTherapeutics (NASDAQ: SONN) Announces Issuance of U.S. Patent for Novel Immunotherapeutic Drug Candidates - Defense World
Sonnet BioTherapeutics secures US patent covering two drug candidates - Pharmaceutical Technology
Sonnet BioTherapeutics secures patent for cancer drug candidates By Investing.com - Investing.com Australia
SONN stock touches 52-week high at $9.9 amid market optimism - Investing.com Australia
Sonnet BioTherapeutics Prices of $5.0 Million Underwritten Public Offering - citybiz
Sonnet BioTherapeutics Announces Pricing of $5.0 Million - GlobeNewswire
Sonnet BioTherapeutics sets $5 million stock offering - Investing.com India
Sonnet BioTherapeutics sets $5 million stock offering By Investing.com - Investing.com UK
Sonnet BioTherapeutics Raises $5M in Stock Offering with Warrant Coverage | SONN Stock News - StockTitan
Sonnet BioTherapeutics secures patent for cancer drug candidates - Investing.com India
U.S. Stock market: SONN(+86.46%), DataChat(+50.28%), Cytek Biosciences(+30.51%) among the top gainers during early trading - Business Upturn
Sonnet BioTherapeutics Secures Patent for Cancer Drugs - TipRanks
Sonnet BioTherapeutics Announces Issuance of U.S. Patent - GlobeNewswire
Sonnet BioTherapeutics Secures Key Patent for Novel Cancer Immunotherapy Drugs | SONN Stock News - StockTitan
Sonnet BioTherapeutics Announces Issuance of U.S. Patent Covering a Variant IL-18 Incorporated into Two Novel Immunotherapeutic Drug Candidates - Yahoo Finance
Sonnet stock tumbles 22% in wake of proposed offering filing - MSN
(SONN) On The My Stocks Page - Stock Traders Daily
When (SONN) Moves Investors should Listen - Stock Traders Daily
Sonnet BioTherapeutics (SONN) Stock Surges After Regaining Nasdaq Compliance - Stocks Telegraph
Sonnet BioTherapeutics Maintains Nasdaq Listing Compliance - TipRanks
Sonnet BioTherapeutics Inc. Regains Compliance with Nasdaq - GlobeNewswire
SONN (Sonnet BioTherapeutics Holdings) Capex-to-Operating-C - GuruFocus.com
Sonnet BioTherapeutics Enters into Licensing Agreement with Alkem Laboratories for DPN in India - Chemical Industry Digest
Alkem Labs inks pact with Sonnet BioTherapeutics to develop, commercialise drug candidate for diabetic... - Medical Dialogues
Alkem Labs partners with Sonnet BioTherapeutics to develop drug candidate for diabetic peripheral neuropathy in India - BSI bureau
Alkem Labs enters into licensing agreement with Sonnet BioTherapeutics for its diabetic peripheral neuropathy drug in India - The Financial Express
Alkem Laboratories enters into a licensing agreement with US-based Sonnet BioTherapeutics - Equity Bulls
Alkem inks licensing pact with Sonnet BioTherapeutics for drug to treat diabetic neuropathy - Press Trust of India
Sonnet BioTherapeutics’ Strategic Deal to Develop DPN Treatment - Yahoo Finance
Alkem Licenses Drug for Diabetic Neuropathy in India - Rediffmail
Alkem and Sonnet BioTherapeutics Team Up for Diabetic Neuropathy Treatment - Devdiscourse
Sonnet BioTherapeutics Inc. Enters into Licensing Agreement with Alkem Laboratories Limited to Develop and Commercialize SON-080 for Diabetic Peripheral Neuropathy (DPN) in India - The Manila Times
Sonnet BioTherapeutics, Alkem enter licensing agreement for SON-080 - TipRanks
SONN stock touches 52-week low at $4.8 amid market challenges By Investing.com - Investing.com South Africa
SONN stock touches 52-week low at $4.8 amid market challenges - Investing.com India
Sonnet BioTherapeutics receives funding through NJEDA, Australia tax programs - TipRanks
Sonnet BioTherapeutics secures tax credit approval By Investing.com - Investing.com Australia
Sonnet BioTherapeutics secures tax credit approval - Investing.com India
Sonnet BioTherapeutics to Receive Non-Dilutive Funding Through New Jersey Tax Certificate Transfer and Australia R&D Tax Incentive Programs - ForexTV.com
Sonnet BioTherapeutics to Receive Non-Dilutive Funding - GlobeNewswire
Sonnet BioTherapeutics launches CEO Corner platform - Investing.com
Sonnet BioTherapeutics enacts reverse stock split By Investing.com - Investing.com Australia
Sonnet BioTherapeutics enacts reverse stock split - Investing.com India
Finanzdaten der Sonnet Biotherapeutics Holdings Inc-Aktie (SONN)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):